Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma

BACKGROUND: Glycogen synthase kinase (GSK)-3β has emerged as an appealing therapeutic target for glioblastoma (GBM). Here, we investigated the therapeutic effect of the current approved drugs against GBM via inhibition of GSK3β activity both, in experimental setting and in a clinical study for recur...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncotarget
Κύριοι συγγραφείς: Furuta, Takuya, Sabit, Hemragul, Dong, Yu, Miyashita, Katsuyoshi, Kinoshita, Masashi, Uchiyama, Naoyuki, Hayashi, Yasuhiko, Hayashi, Yutaka, Minamoto, Toshinari, Nakada, Mitsutoshi
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Impact Journals LLC 2017
Θέματα:
Research Paper
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5410264/
https://ncbi.nlm.nih.gov/pubmed/28423558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15206
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια